Form 4: Nautilus Biotechnology Executive Gwen Weld Acquires 160,000 Stock Options

Gwen Weld, Chief People Officer of Nautilus Biotechnology, acquired 160,000 stock options on March 3, 2025, according to a recent SEC filing.

Summary

• On March 3, 2025, Gwen Weld, the Chief People Officer of Nautilus Biotechnology, acquired 160,000 stock options at an exercise price of $1.24.
• These options vest over a period of 4 years, starting January 1, 2025, according to the company's 2021 Equity Incentive Plan.
• 25% of the shares vest on the first anniversary of the Vesting Commencement Date, and the remaining shares vest monthly over the following 36 months.
• Weld also has a Power of Attorney agreement, granting specific individuals the authority to act on her behalf in matters related to SEC filings and securities transactions.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.

Positives

• The grant of stock options to a key executive aligns their interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests an expectation of continued employment and contribution from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotechnology companies.
• Vesting schedules of 3-4 years are typical to incentivize long-term commitment.
• The specific number of options granted and the exercise price would be benchmarked against similar roles and company size within the industry.

Stakeholder Impact

• Shareholders: The grant of stock options can be seen as a positive sign, aligning executive interests with shareholder value.
• Employees: The grant of stock options to a key executive can boost employee morale.
• Executive: The grant of stock options incentivizes the executive to perform well and contribute to the company's success.

Key Dates